Platelet-Rich Plasma: New Performance Understandings and Therapeutic Considerations in 2020
International Journal of Molecular Sciences · 2020
A widely-cited PRP mechanism review, not a clinical trial — it explains the biology, not whether PRP actually works for your patient.
The paper
Narrative review (non-systematic), no original patient cohort — synthesizes in vitro, animal, and human PRP literature on formulation and mechanism.
What they found
No quantitative clinical outcomes are reported. The review summarizes proposed mechanisms (platelet growth factor release, leukocyte-driven immunomodulation, serotonin/pain effects, angiogenesis) and argues that PRP formulation variables (platelet dose, leukocyte content) explain inconsistent clinical results across studies.
The appraisal
This is a mechanistic/narrative review, not a controlled study — there is no described systematic search strategy, no risk-of-bias assessment, and no pooled effect estimates, so it cannot itself establish efficacy. Its value is conceptual: explaining why heterogeneous PRP preparations produce conflicting RCT results, not demonstrating that any specific PRP protocol works. The abstract explicitly flags that non-clinical (in vitro/animal) findings often fail to translate to human outcomes, which is an honest and important caveat but also underscores the evidence gap.
The gap
It doesn't tell you which PRP formulation (platelet count, leukocyte-rich vs. -poor, activation method) actually improves patient-relevant outcomes for a given condition — that requires standardized-formulation RCTs with clinical endpoints, which this review does not provide.
Landmark context
Sits within the long-running PRP classification debate (e.g., Mishra/DEPA-type classification systems) that arose precisely because unstandardized formulations made trials like those in Achilles and patellar tendinopathy hard to compare or replicate; this paper extends that mechanistic rationale rather than resolving the RCT heterogeneity itself.
What to do Monday
No — this doesn't change Monday's practice. It's background reading that should make clinicians more skeptical of generic 'PRP' as a single intervention and more attentive to reported formulation details when appraising any individual PRP trial or product.
The five papers that matter — every week, free.
We read the whole sports-medicine, rehab & performance literature and appraise the papers worth your time.
Get the free weekly issueRelated appraisals
Read in your language: English · Français · Deutsch · Español · Italiano · Nederlands · Dansk · Svenska